Deborah Schrag

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. doi request reprint American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 29:3328-30. 2011
  2. doi request reprint Evolving role of neoadjuvant therapy in rectal cancer
    Deborah Schrag
    Dana Farber Cancer Institute, Boston, MA, 02215, USA
    Curr Treat Options Oncol 14:350-64. 2013
  3. pmc Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer
    Hanna K Sanoff
    Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA
    J Natl Cancer Inst 104:211-27. 2012
  4. ncbi request reprint Linking tumor registry and Medicaid claims to evaluate cancer care delivery
    Deborah Schrag
    Dana Farber Cancer Institute, Boston, MA 02116, USA
    Health Care Financ Rev 30:61-73. 2009
  5. pmc Underuse of hospice care by Medicaid-insured patients with stage IV lung cancer in New York and California
    Jennifer W Mack
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 31:2569-79. 2013
  6. pmc Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years
    Hanna K Sanoff
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 30:2624-34. 2012
  7. pmc Regional variation in spending and survival for older adults with advanced cancer
    Gabriel A Brooks
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    J Natl Cancer Inst 105:634-42. 2013
  8. doi request reprint Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer
    Thomas A Abrams
    Affiliations of authors Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA TAA, DS, JAM, CSF IntrinsiQ, LLC, an AmerisourceBergen Specialty Group Company, Burlington, MA GM, JM
    J Natl Cancer Inst 106:djt371. 2014
  9. pmc Expectations about the effectiveness of radiation therapy among patients with incurable lung cancer
    Aileen B Chen
    Dana Farber Cancer Institute, 450 Brookline Ave, D1111, Boston, MA 02215, USA
    J Clin Oncol 31:2730-5. 2013
  10. doi request reprint Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer
    Junya Zhu
    Center for Patient Safety, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer 119:2048-60. 2013

Detail Information

Publications50

  1. doi request reprint American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays
    Harold J Burstein
    Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 29:3328-30. 2011
    ..To update the American Society of Clinical Oncology (ASCO) Technology Assessment guidelines on chemotherapy sensitivity and resistance assays (CSRAs) published in 2004...
  2. doi request reprint Evolving role of neoadjuvant therapy in rectal cancer
    Deborah Schrag
    Dana Farber Cancer Institute, Boston, MA, 02215, USA
    Curr Treat Options Oncol 14:350-64. 2013
    ..To determine if therapy can be streamlined, participation in PROSPECT or other clinical trials asking compelling clinical questions is a priority...
  3. pmc Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer
    Hanna K Sanoff
    Division of Hematology and Oncology, Department of Medicine, University of Virginia, Charlottesville, VA, USA
    J Natl Cancer Inst 104:211-27. 2012
    ..However, RCT participants are younger, healthier, and less racially diverse than the general cancer population. Thus, the benefit of oxaliplatin outside RCTs is uncertain...
  4. ncbi request reprint Linking tumor registry and Medicaid claims to evaluate cancer care delivery
    Deborah Schrag
    Dana Farber Cancer Institute, Boston, MA 02116, USA
    Health Care Financ Rev 30:61-73. 2009
    ..We found that Medicaid claims have moderate sensitivity for identifying cancer diagnoses and surgery. Linked registry-Medicaid data can identify indigent patients and the timing of Medicaid coverage...
  5. pmc Underuse of hospice care by Medicaid-insured patients with stage IV lung cancer in New York and California
    Jennifer W Mack
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 31:2569-79. 2013
    ..Medicare patients with advanced cancer have low rates of hospice use. We sought to evaluate hospice use among patients in Medicaid, which insures younger and indigent patients, relative to those in Medicare...
  6. pmc Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years
    Hanna K Sanoff
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 30:2624-34. 2012
    ..Few patients 75 years of age and older participate in clinical trials, thus whether adjuvant chemotherapy for stage III colon cancer (CC) benefits this group is unknown...
  7. pmc Regional variation in spending and survival for older adults with advanced cancer
    Gabriel A Brooks
    Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    J Natl Cancer Inst 105:634-42. 2013
    ..Medicare spending varies substantially across the United States. We evaluated the association between mean regional spending and survival in advanced cancer...
  8. doi request reprint Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer
    Thomas A Abrams
    Affiliations of authors Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA TAA, DS, JAM, CSF IntrinsiQ, LLC, an AmerisourceBergen Specialty Group Company, Burlington, MA GM, JM
    J Natl Cancer Inst 106:djt371. 2014
    ..Since the introduction of biologic therapies for the treatment of metastatic colorectal cancer (mCRC), few studies have examined patterns of care or predictors of specific treatment approaches...
  9. pmc Expectations about the effectiveness of radiation therapy among patients with incurable lung cancer
    Aileen B Chen
    Dana Farber Cancer Institute, 450 Brookline Ave, D1111, Boston, MA 02215, USA
    J Clin Oncol 31:2730-5. 2013
    ..Although radiation therapy (RT) can palliate symptoms and may prolong life, it is not curative for patients with metastatic lung cancer. We investigated patient expectations about the goals of RT for incurable lung cancers...
  10. doi request reprint Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer
    Junya Zhu
    Center for Patient Safety, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer 119:2048-60. 2013
    ..Their relative effectiveness and comparability based on squamous versus nonsquamous histology is uncertain...
  11. pmc Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer
    Rachel L Yung
    Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA
    J Natl Cancer Inst 104:1102-5. 2012
    ..Partnerships between Medicaid programs and cancer registries may help identify at-risk women and facilitate the implementation of quality improvement strategies...
  12. pmc Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 18:377-8. 2013
    ..We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor)...
  13. pmc Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis
    Hanna K Sanoff
    Department of Medicine, Division of Hematology and Oncology, University of Virginia, Charlottesville, Virginia, USA
    Cancer 118:4309-20. 2012
    ..However, the tolerability of this in the general population of patients with colon cancer is uncertain...
  14. pmc Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer
    Junya Zhu
    Center for Patient Safety, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    JAMA 307:1593-601. 2012
    ..However, longer survival was not observed in the subgroup of patients aged 65 years or older...
  15. pmc Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 30:608-15. 2012
    ..Clinical trials have shown that adding bevacizumab to cytotoxic chemotherapy improves survival for patients with colorectal cancer, although its effectiveness in the Medicare population is uncertain...
  16. ncbi request reprint Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:166-74. 2004
    ..However, because these studies often lack detailed information on tumor and treatment characteristics as well as cancer recurrence, the true nature of this relation remains uncertain...
  17. doi request reprint Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer
    Thomas A Abrams
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 29:3255-62. 2011
    ..Previous studies have examined predictors for initiation of adjuvant chemotherapy in stages II and III colon cancer. However, little is known regarding the use of specific chemotherapy regimens or treatment duration...
  18. doi request reprint Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors
    Geoffrey Y Ku
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer Invest 27:402-6. 2009
    ..We performed a phase I study of 5-fluorouracil (5-FU), cisplatin and irinotecan...
  19. pmc Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303)
    Dorothy Romanus
    Massachusetts General Hospital, Harvard School of Public Health, Boston, Massachusetts, USA
    J Pain Symptom Manage 43:205-17. 2012
    ..Gemcitabine for advanced pancreatic cancer (APC) is palliative and the prognosis is poor, making health-related quality of life (HRQOL) particularly important...
  20. pmc Secular trends in colon and rectal cancer relative survival
    Carolyn M Rutter
    Affiliations of authors Group Health Research Institute, Seattle, WA CMR, EAJ Division of Cancer Control and Population Sciences National Cancer Institute, Bethesda, MD EJF Institute for Technology Assessment, Department of Radiology, Massachusetts General Hospital, Boston MA ABK Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis MN KMK Division of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA DS
    J Natl Cancer Inst 105:1806-13. 2013
    ..Relative survival is a metric that accounts for these concurrent changes, allowing assessment of changes in CRC survival. We describe stage- and location-specific trends in relative survival after CRC diagnosis...
  21. pmc Palliative radiation therapy practice in patients with metastatic non-small-cell lung cancer: a Cancer Care Outcomes Research and Surveillance Consortium (CanCORS) Study
    Aileen B Chen
    Dana Farber Cancer Institute, 450 Brookline Ave, D1111, Boston, MA 02215, USA
    J Clin Oncol 31:558-64. 2013
    ..We investigated population-based patterns in the use of palliative RT among patients with metastatic non-small-cell lung cancer (NSCLC)...
  22. pmc Patients' expectations about effects of chemotherapy for advanced cancer
    Jane C Weeks
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    N Engl J Med 367:1616-25. 2012
    ..Chemotherapy for metastatic lung or colorectal cancer can prolong life by weeks or months and may provide palliation, but it is not curative...
  23. pmc Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38231. 2012
    ..To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer...
  24. pmc Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study
    S Yousuf Zafar
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    BMC Cancer 11:354. 2011
    ..We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment...
  25. ncbi request reprint Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients
    Craig C Earle
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 98:172-80. 2006
    ..e., better outcomes). We examined associations between physician specialty and outcomes in a population-based cohort of elderly ovarian cancer surgery patients...
  26. ncbi request reprint Association of hospital procedure volume and outcomes in patients with colon cancer at high risk for recurrence
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Eastern Cooperative Oncology Group Statistical Center, and Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Intern Med 139:649-57. 2003
    ..However, because such administrative data lack information on cancer recurrence, the true nature of this relation remains uncertain...
  27. doi request reprint Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis
    David J Sher
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 81:e197-206. 2011
    ....
  28. doi request reprint Identification of potentially avoidable hospitalizations in patients with GI cancer
    Gabriel A Brooks
    All authors Dana Farber Cancer Institute, Boston, MA
    J Clin Oncol 32:496-503. 2014
    ..To identify and characterize potentially avoidable hospitalizations in patients with GI malignancies...
  29. doi request reprint What do cancer patients worry about when making decisions about treatment? Variation across racial/ethnic groups
    Michelle Y Martin
    Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham, 1717 11th Avenue South, MT 617, Birmingham, AL, 35205, USA
    Support Care Cancer 22:233-44. 2014
    ..Understanding the source of patient worry and identifying interventions to alleviate worry are important to delivering patient-centered cancer care...
  30. doi request reprint Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions
    Gregory A Abel
    Division of Population Sciences, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer 119:1065-72. 2013
    ....
  31. pmc Modeling the effectiveness of initial management strategies for ductal carcinoma in situ
    Djøra I Soeteman
    Center for Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA
    J Natl Cancer Inst 105:774-81. 2013
    ..We sought to quantify the tradeoffs among alternative management strategies for DCIS with respect to disease outcomes and breast preservation...
  32. pmc Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies
    Teppei Morikawa
    Department of Medical Oncology, Dana Farber Cancer Institute and Havard Medical School, Boston, MA 02215, USA
    Arch Surg 147:715-23. 2012
    ..To identify factors that influence the total and negative lymph node counts in colorectal cancer resection specimens independent of pathologists and surgeons...
  33. pmc Receipt of appropriate surgical care for Medicare beneficiaries with cancer
    Caprice C Greenberg
    Center for Surgery and Public Health, Department of Surgery, Brigham and Women s Hospital, Boston, MA 02115, USA
    Arch Surg 146:1128-34. 2011
    ..To investigate receipt of appropriate surgical care in Medicare beneficiaries with cancer...
  34. ncbi request reprint Neoadjuvant Radiotherapy Use in Locally Advanced Rectal Cancer at NCCN Member Institutions
    Marsha Reyngold
    From aDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York bDepartments of Information Sciences and cBiostatistics, City of Hope Comprehensive Cancer Center, Duarte, California dDepartment of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, Massachusetts eDivision of Medical Oncology, Department of Medicine, The Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute, Columbus, Ohio fDepartment of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania gDepartment of Surgical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California hDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas iDepartment of Radiation Oncology, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois jDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York and kDepartment of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York
    J Natl Compr Canc Netw 12:235-43. 2014
    ....
  35. pmc Delivering high-quality and affordable care throughout the cancer care continuum
    Ya Chen Tina Shih
    Ya Chen Tina Shih, University of Chicago, Chicago IL Patricia A Ganz, Denise Aberle, and Jim C Hu, University of California at Los Angeles, Los Angeles, CA Amy Abernethy, Duke University, Durham, NC Justin Bekelman, University of Pennsylvania, Philadelphia, PA Otis Brawley, American Cancer Society, Atlanta, GA James S Goodwin, University of Texas, Galveston, TX Deborah Schrag, Dana Farber Cancer Institute and Jennifer S Temel and Lowell Schnipper, Harvard Medical School, Boston, MA
    J Clin Oncol 31:4151-7. 2013
    ..This article is our summary of presentations at the workshop that highlighted the overuse and underuse of screening, treatments, and technologies throughout the cancer care continuum in oncology practice in the United States. ..
  36. pmc Feasibility of computer-based self-administered cancer-specific geriatric assessment in older patients with gastrointestinal malignancy
    Nadine J McCleary
    Dana Farber Cancer Institute, Department of Medical Oncology, Gastrointestinal Oncology, 450 Brookline Avenue, Boston, MA 02215, USA
    Oncologist 18:64-72. 2013
    ..The Cancer-Specific Geriatric Assessment (CSGA) is a primarily self-administered paper survey of validated measures...
  37. pmc Rescreening of persons with a negative colonoscopy result: results from a microsimulation model
    Amy B Knudsen
    Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, 10th Floor, Boston, MA 02114, USA
    Ann Intern Med 157:611-20. 2012
    ..Persons with a negative result on screening colonoscopy are recommended to repeat the procedure in 10 years...
  38. pmc Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 117:5094-102. 2011
    ..The phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway plays a critical role in the pathogenesis of hepatocellular carcinoma (HCC). We performed a single-arm, phase 1/2 study of everolimus in patients with advanced HCC...
  39. pmc Cancer disparities in the context of Medicaid insurance: a comparison of survival for acute myeloid leukemia and Hodgkin's lymphoma by Medicaid enrollment
    Rachel L Yung
    Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 16:1082-91. 2011
    ..Using Medicaid enrollment as a proxy for poverty, we aimed to assess potential disparities in survival after a diagnosis of acute myeloid leukemia (AML) or Hodgkin's lymphoma (HL) in a nonelderly population...
  40. doi request reprint American Society of Clinical Oncology guidance statement: the cost of cancer care
    Neal J Meropol
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 27:3868-74. 2009
    ..Doing so will require a clear understanding of the factors that drive these costs, as well as potential modifications to the current cancer care system to ensure that all Americans have access to high-quality, cost-effective care...
  41. doi request reprint Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation
    Aileen B Chen
    Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    J Clin Oncol 29:2305-11. 2011
    ..Technical studies suggest that computed tomography (CT) -based simulation improves the therapeutic ratio for thoracic radiation therapy (TRT), although few studies have evaluated its use or impact on outcomes...
  42. pmc Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer
    William P Tew
    Gynecologic Medical Oncology, Medical Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 27:366-73. 2009
    ..To determine the maximum tolerated dose (MTD), toxicities, and suitable dose for weekly 1-h paclitaxel combined with weekly cisplatin and irinotecan to treat advanced gastrointestinal malignancies...
  43. ncbi request reprint Using propensity scores to estimate the cost-effectiveness of medical therapies
    Alka Indurkhya
    Department of Society, Human Development and Health, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA
    Stat Med 25:1561-76. 2006
    ..Our method is illustrated by applying it to SEER-Medicare data for muscle invasive bladder cancer to determine the most cost-effective treatment protocol...
  44. pmc Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection
    Deborah Schrag
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Department of Medicine, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 236:583-92. 2002
    ..To compare surgeon and hospital procedure volume as predictors of outcomes for patients with rectal cancer...
  45. doi request reprint Stakeholder engagement for comparative effectiveness research in cancer care: experience of the DEcIDE Cancer Consortium
    Caprice C Greenberg
    Department of Medical Oncology, Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA, USA
    J Comp Eff Res 2:117-25. 2013
    ..These recommendations can inform other initiatives currently facing the challenges of engaging stakeholders in priority setting for cancer. ..
  46. ncbi request reprint A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic
    Elizabeth Y Chiao
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Acquir Immune Defic Syndr 40:451-5. 2005
    ..The incidence of SCCA has particularly increased among men and those between 30 and 54 years of age since the introduction of HAART...
  47. ncbi request reprint Cetuximab therapy and symptomatic hypomagnesemia
    Deborah Schrag
    Division of Gastrointestinal Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 221, New York, NY 10011, USA
    J Natl Cancer Inst 97:1221-4. 2005
    ..Because symptoms may be rapidly ameliorated with supplementation, we suggest that, when fatigue or hypocalcemia is encountered during cetuximab therapy, serum magnesium level be measured and repleted as necessary...
  48. ncbi request reprint Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis
    Dorothy Romanus
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Natl Compr Canc Netw 7:895-904. 2009
    ..The Colorectal Cancer Database began in 2005 as a collaboration among 8 NCCN centers...
  49. pmc Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities
    Ethan Basch
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Med Inform Assoc 14:264-8. 2007
    ..Ongoing multi-center research will evaluate the impact of this approach on clinical and administrative outcomes...
  50. pmc Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer
    Andrea C Phelps
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    JAMA 301:1140-7. 2009
    ..Patients frequently rely on religious faith to cope with cancer, but little is known about the associations between religious coping and the use of intensive life-prolonging care at the end of life...